National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

Simple item page
dc.contributor.authorDursun, A
dc.contributor.authorBavbek, S
dc.contributor.authorMisirligil, Z
dc.contributor.authorErdener, F
dc.contributor.authorBuyukozturk, S
dc.contributor.authorAydin, O
dc.contributor.authorGemicioglu, B
dc.contributor.authorBayrak, P
dc.contributor.authorErkekol, FO
dc.contributor.authorYildirim, Z
dc.contributor.authorCilli, A
dc.contributor.authorBoz, AB
dc.contributor.authorAlpaydyn, AO
dc.contributor.authorKarakoc, G
dc.contributor.authorGorguner, M
dc.contributor.authorKarakaya, G
dc.contributor.authorIsik, R
dc.contributor.authorSapan, N
dc.contributor.authorBakirtas, A
dc.date.accessioned2024-07-18T12:08:00Z
dc.date.available2024-07-18T12:08:00Z
dc.identifier.issn0105-4538
dc.identifier.other1398-9995
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10751
dc.language.isoEnglish
dc.publisherWILEY-BLACKWELL
dc.titleNational safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey
dc.typeMeeting Abstract

Files

Collections

Web of Science Koleksiyonu